Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,361 active trials259 approved drugs3,860 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,753 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04914845 | KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia | completed | Phase 1 | 16 | University of Colorado, DenverOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT04991480 | A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors | completed | Phase 1 | 93 | Artios Pharma LtdINDUSTRY | 2 | Jan 27, 2026 | clinicaltrials |
| completed |
| Phase 1 |
| 172 |
| Boehringer IngelheimINDUSTRY |
| 5 |
| Jan 26, 2026 |
| clinicaltrials |
| NCT05040568 | A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD) | completed | Phase 1 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT05665530 | A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies | completed | Phase 1 | 86 | Prelude TherapeuticsINDUSTRY | 10 | Jan 26, 2026 | clinicaltrials |
| NCT00625755 | A Phase I/II Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusions in Patients With AJCC Stage IV Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 40 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT00626860 | The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma | completed | Phase 1 / Phase 2 | 20 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT01175356 | Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin | completed | Phase 1 | 99 | Children's Oncology GroupNETWORK | 1 | Jan 23, 2026 | clinicaltrials |
| NCT03262636 | Two-Part Study to Evaluate the Safety and Efficacy of Image Guided Surgery Using Indocyanine Green for Intramolecular Imaging of Nervous System Tumors Compared to Standard of Care, (TumorGlow)(TumorGlow(TM)) | completed | Phase 1 | 363 | University of PennsylvaniaOTHER | 0 | Jan 23, 2026 | clinicaltrials |
| NCT04139434 | Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML | completed | Phase 1 | 32 | Newave Pharmaceutical IncINDUSTRY | 2 | Jan 23, 2026 | clinicaltrials |
| NCT03978689 | A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma | completed | Phase 1 | 80 | Cue BiopharmaINDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT05360680 | A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers | completed | Phase 1 | 42 | Cue BiopharmaINDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT03578406 | HPV-E6-Specific Anti-PD1 TCR-T Cells in the Treatment of HPV-Positive NHSCC or Cervical Cancer | completed | Phase 1 | 9 | Xinqiao Hospital of ChongqingOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT03889912 | Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma | completed | Phase 1 | 97 | Regeneron PharmaceuticalsINDUSTRY | 3 | Jan 21, 2026 | clinicaltrials |
| NCT03003468 | Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017 | completed | Phase 1 / Phase 2 | 35 | Lawrence Feldman, MDOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT03575793 | A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 39 | Salma SabbourOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT03994601 | An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers | completed | Phase 1 / Phase 2 | 219 | Bristol-Myers SquibbINDUSTRY | 7 | Jan 20, 2026 | clinicaltrials |
| NCT04139057 | EBV-Specific Anti-PD1 TCR-T Cells in the Treatment of EBV-Positive NHSCC | completed | Phase 1 / Phase 2 | 10 | Xinqiao Hospital of ChongqingOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT04440358 | Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBM | completed | Phase 1 / Phase 2 | 13 | InSightecINDUSTRY | 3 | Jan 20, 2026 | clinicaltrials |
| NCT04509726 | EBV Specific Cytokine Secreting TCR-T Cells in the Treatment of EBV-Positive Metastatic/Refractory Nasopharyngeal Carcinoma | completed | Phase 1 / Phase 2 | 9 | Xinqiao Hospital of ChongqingOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT04627740 | Anti-ALPP CAR-T Cells Immunotherapy for Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 5 | Xinqiao Hospital of ChongqingOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT06553157 | Statins Effect on Incidence of Side Effects of Platinum Based Chemotherapy | completed | Phase 1 / Phase 2 | 56 | Minia UniversityOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT06556108 | ALPP CAR-T Cells for ALPP-Positive Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 5 | Xinqiao Hospital of ChongqingOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT02312102 | Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation | completed | Phase 1 | 22 | Massachusetts General HospitalOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT04109456 | IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma | completed | Phase 1 | 51 | InxMed (Shanghai) Co., Ltd.INDUSTRY | 2 | Jan 15, 2026 | clinicaltrials |
| NCT02805725 | Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly Trabectedin Combined With Metronomic Cyclophosphamide(TARMIC) | completed | Phase 1 / Phase 2 | 50 | Institut BergoniéOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT05276284 | Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy(TEMPLE) | completed | Phase 1 / Phase 2 | 18 | Kristoffer RohrbergOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT05375903 | A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) | completed | Phase 1 | 51 | UroGen Pharma Ltd.INDUSTRY | 3 | Jan 14, 2026 | clinicaltrials |
| NCT07229560 | A Trial of Itraconazole Effect on HRS-8080 Pharmacokinetics in Healthy Participants | completed | Phase 1 | 16 | Shandong Suncadia Medicine Co., Ltd.INDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT00596648 | A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 / Phase 2 | 92 | ExelixisINDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT02264613 | ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas | completed | Phase 1 / Phase 2 | 142 | Aileron Therapeutics, Inc.INDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT04587479 | A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors | completed | Phase 1 | 41 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT04773782 | A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling | completed | Phase 1 / Phase 2 | 29 | Blueprint Medicines CorporationINDUSTRY | 9 | Jan 13, 2026 | clinicaltrials |
| NCT05002270 | JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation | completed | Phase 1 / Phase 2 | 29 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT06840548 | A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoCAIX in Patients With CAIX-positive Cancer(OncoCAIX) | completed | Phase 1 | 20 | Philogen S.p.A.INDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT05337137 | A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer(RELATIVITY-106) | completed | Phase 1 / Phase 2 | 83 | Bristol-Myers SquibbINDUSTRY | 15 | Jan 12, 2026 | clinicaltrials |
| NCT06558513 | To Evaluate a Phase I/II Clinical Study of XNW5004 Tablets in Patients With Relapsed/Refractory Advanced Tumors | completed | Phase 1 / Phase 2 | 120 | Evopoint Biosciences Inc.INDUSTRY | 1 | Jan 12, 2026 | clinicaltrials |
| NCT03685331 | HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer | completed | Phase 1 | 9 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT04134117 | Tisagenlecleucel In Primary CNS Lymphoma | completed | Phase 1 | 13 | Matthew J. Frigault, M.D.OTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT04220684 | Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML | completed | Phase 1 | 19 | Sumithira VasuOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT06095375 | Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients(REGOMA-2) | completed | Phase 1 | 21 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT03042689 | Study of Regorafenib in Patients With Advanced Myeloid Malignancies | completed | Phase 1 | 16 | Massachusetts General HospitalOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT03510104 | Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Solid Tumors | completed | Phase 1 | 42 | Meryx, Inc.INDUSTRY | 1 | Jan 8, 2026 | clinicaltrials |
| NCT00085930 | Blood T-Cells and EBV Specific CTLs Expressing GD-2 Specific Chimeric T Cell Receptors to Neuroblastoma Patients(NESTLES) | completed | Phase 1 | 19 | Baylor College of MedicineOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT03905148 | Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors | completed | Phase 1 | 91 | BeiGeneINDUSTRY | 2 | Jan 7, 2026 | clinicaltrials |
| NCT04175847 | A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors | completed | Phase 1 / Phase 2 | 198 | RemeGen Co., Ltd.INDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT03290937 | Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer | completed | Phase 1 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT03702725 | Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma | completed | Phase 1 | 14 | Alliance Foundation Trials, LLC.OTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT04617314 | A Study of RC108-ADC in Subjects With Advanced Malignant Solid Tumors | completed | Phase 1 | 67 | RemeGen Co., Ltd.INDUSTRY | 1 | Jan 6, 2026 | clinicaltrials |
| NCT05174585 | JAB-BX102 Monotherapy and Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 21 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 6, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Jan 27, 2026source: clinicaltrials